All In Biotech

Drug Trial Radar · NCT04433234

Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy

A Phase II, Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

8

Planned (sponsor's estimate)

Start

Jun 30, 2020

Primary completion

Jan 31, 2027

Study completion Jan 31, 2031

Sponsor

Lead sponsor
Daiichi Sankyo Co., Ltd.Daiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
Jun 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, long-term, extension, phase 2 study to evaluate the safety and efficacy of long-term treatment with DS-5141b in patients with DMD who have completed DS5141-A-J101.

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • DS-5141bDrug

    Administered via subcutaneous injection once weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs)Time frame: From first injection to after the last injection of DS-5141b in this study (within approximately 2 years)
  2. Change in distance walked during 6-minute walk test (6MWT)Time frame: Every 3 months (within approximately 2 years)
  3. Change in time to stand (TTSTAND)Time frame: Every 3 months (within approximately 2 years)
  4. Change in time in Timed up and go testTime frame: Every 3 months (within approximately 2 years)
  5. Change in time in 10-meter Run/Walk testTime frame: Every 3 months (within approximately 2 years)
  6. Change in score in the North Star Ambulatory Assessment (NSAA)Time frame: Every 3 months (within approximately 2 years)
  7. Change in score in the Performance of Upper Limb (PUL)Time frame: Every 3 months (within approximately 2 years)
  8. Change in Left Ventricular Ejection Fraction percentage (LVEF %)Time frame: Every 6 months (within approximately 2 years)
  9. Change in in Forced Vital Capacity (FVC) (percent predicted)Time frame: Every 6 months (within approximately 2 years)
  10. Change in Muscle Strength Measured by Quantitative Muscle Strength AssessmentTime frame: Every 3 months (within approximately 2 years)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Kobe University Hospital

    Hyōgo, Japan

  • National Center of Neurology and Psychiatry

    Tokyo, Kodaira-Shi, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.